215
Views
52
CrossRef citations to date
0
Altmetric
Review

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors

, , &
Pages 2745-2758 | Published online: 30 Aug 2016

References

  • MendellJRShillingCLeslieNDEvidence-based path to newborn screening for Duchenne muscular dystrophyAnn Neurol201271330431322451200
  • HoffmanEPBrownRHJrKunkelLMDystrophin: the protein product of the Duchenne muscular dystrophy locusCell19875169199283319190
  • LjubicicVBurtMJasminBJThe therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targetsFASEB J201428254856824249639
  • OguraYTajrishiMMSatoSHindiSMKumarATherapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophyFront Cell Dev Biol201421125364719
  • CirakSArechavala-GomezaVGuglieriMExon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyLancet2011378979159560521784508
  • MojumdarKLiangFGiordanoCInflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2EMBO Mol Med20146111476149225312642
  • GiordanoCMojumdarKLiangFToll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophyHum Mol Genet20152482147216225552658
  • VillaltaSANguyenHXDengBGotohTTidballJGShifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophyHum Mol Genet200918348249618996917
  • FindlayARWeinNKaminohYClinical phenotypes as predictors of the outcome of skipping around DMD exon 45Ann Neurol201577466867425612243
  • KoleRKrainerARAltmanSRNA therapeutics: beyond RNA interference and antisense oligonucleotidesNat Rev2012112125140
  • WoodMJGaitMJYinHRNA-targeted splice-correction therapy for neuromuscular diseaseBrain2010133Pt 495797220150322
  • KooTWoodMJClinical trials using antisense oligonucleotides in Duchenne muscular dystrophyHum Gene Ther201324547948823521559
  • Aartsma-RusAFokkemaIVerschuurenJTheoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutationsHum Mutat200930329329919156838
  • AhimaRSParkHKConnecting myokines and metabolismEndocrinol Metab2015303235245
  • BonifatiMDRuzzaGBonomettoPA multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophyMuscle Nerve20002391344134710951436
  • EscolarDMHacheLPClemensPRRandomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophyNeurology201177544445221753160
  • FalzaranoMSScottonCPassarelliCFerliniADuchenne muscular dystrophy: from diagnosis to therapyMolecules20152010181681818426457695
  • HuizengaNAKoperJWDe LangePA polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivoJ Clin Endocrinol Metab19988311441519435432
  • WolthersODPedersenSShort term linear growth in asthmatic children during treatment with prednisoloneBMJ199030167441451482202451
  • AvioliLVGlucocorticoid effects on statural growthBr J Rheumatol199332Suppl 227308495277
  • GroundsMDShavlakadzeTGrowing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disordersBioEssays201133645846821500235
  • RicciottiEFitzGeraldGAProstaglandins and inflammationArterioscler ThrombVasc Biol20113159861000
  • SerraFQuartaMCanatoMInflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugsMuscle Nerve201246577378422847332
  • MartinezLErmolovaNVIshikawaTOStoutDBHerschmanHRSpencerMJA reporter mouse for optical imaging of inflammation in mdx musclesSkelet Muscle201551525949789
  • SchaecherKGoustJMBanikNLThe effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sitesNeurochem Res20042971443145115202778
  • AcharyyaSVillaltaSABakkarNInterplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophyJ Clin Invest2007117488990117380205
  • VillaltaSARosenbergASBluestoneJAThe immune system in Duchenne muscular dystrophy: friend or foeRare Dis201531e101096626481612
  • MillayDPGoonasekeraSASargentMAMailletMAronowBJMolkentinJDCalcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanismProc Natl Acad Sci U S A200910645190231902819864620
  • CooperSTMcNeilPLMembrane repair: mechanisms and pathophysiologyPhysiol Rev20159541205124026336031
  • ZhaoXMoloughneyJGZhangSKomazakiSWeislederNOrai1 mediates exacerbated Ca(2+) entry in dystrophic skeletal musclePloS One2012711e4986223185465
  • GaillyPTRP channels in normal and dystrophic skeletal muscleCurr Opin Pharmacol201212332633422349418
  • GervasioOLWhiteheadNPYeungEWPhillipsWDAllenDGTRPC1 binds to caveolin-3 and is regulated by Src kinase – role in Duchenne muscular dystrophyJ Cell Sci2008121Pt 132246225518544631
  • IwataYKatanosakaYAraiYShigekawaMWakabayashiSDominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal modelsHum Mol Genet200918582483419050039
  • AoyagiKOhara-ImaizumiMNishiwakiCNakamichiYNagamatsuSInsulin/phosphoinositide 3-kinase pathway accelerates the glucose-induced first-phase insulin secretion through TrpV2 recruitment in pancreatic beta-cellsBiochem J2010432237538620854263
  • IwataYKatanosakaYShijunZProtective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cellsBiochem Pharmacol200570574075116009351
  • SwiderskiKTodorovMGehrigSMTranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic miceFibrogenesis Tissue Repair201471124476069
  • VriensJAppendinoGNiliusBPharmacology of vanilloid transient receptor potential cation channelsMol Pharmacol20097561262127919297520
  • BoittinFXPetermannOHirnCCa2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibersJ Cell Sci2006119Pt 183733374216926189
  • LindahlMBackmanEHenrikssonKGGorospeJRHoffmanEPPhospholipase A2 activity in dystrophinopathiesNeuromuscul Disord1995531931997633184
  • WhiteheadNPPhamCGervasioOLAllenDGN-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx miceJ Physiol200858672003201418258657
  • RueggUTPharmacological prospects in the treatment of Duchenne muscular dystrophyCurr Opin Neurol201326557758423995279
  • ItoNRueggUTKudoAMiyagoe-SuzukiYTakedaSActivation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophyNat Med201319110110623202294
  • IsmailHMScapozzaLRueggUTDorchiesOMDiapocynin, a dimer of the NADPH oxidase inhibitor apocynin, reduces ROS production and prevents force loss in eccentrically contracting dystrophic musclePloS One2014910e11070825329652
  • MarxSOMarksARDysfunctional ryanodine receptors in the heart: new insights into complex cardiovascular diseasesJ Mol Cell Cardiol20135822523123507255
  • AnderssonDCMeliACReikenSLeaky ryanodine receptors in beta-sarcoglycan deficient mice: a potential common defect in muscular dystrophySkelet Muscle201221922640601
  • NetheryDCallahanLAStofanDMatteraRDiMarcoASupinskiGPLA(2) dependence of diaphragm mitochondrial formation of reactive oxygen speciesJ Appl Physiol2000891728010904037
  • HauserEHogerHBittnerRWidhalmKHerknerKLubecGOxyradical damage and mitochondrial enzyme activities in the mdx mouseNeuropediatrics19952652602628552217
  • BuyseGMVan der MierenGErbMLong-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performanceEur Heart J200930111612418784063
  • NakaeYHirasakaKGotoJSubcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: a quantitative histological, immunohistochemical and electrophysiological studyHistochem Cell Biol2008129448950118264714
  • DorchiesOMWagnerSVuadensOGreen tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophyAm J Physiol20062902C616C625
  • EvansNPCallJABassaganya-RieraJRobertsonJLGrangeRWGreen tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx miceClin Nutr201029339139819897286
  • HaydenMSGhoshSSignaling to NF-kappaBGenes Dev200418182195222415371334
  • ChenYWNagarajuKBakayMEarly onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophyNeurology200565682683416093456
  • PorterJDKhannaSKaminskiHJA chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx miceHum Mol Genet200211326327211823445
  • PorterJDMerriamAPLeahyPGongBKhannaSDissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) miceHum Mol Genet200312151813182112874102
  • HeierCRDamskerJMYuQVBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effectsEMBO Mol Med20135101569158524014378
  • GroundsMDTorrisiJAnti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosisFASEB J200418667668215054089
  • PiernoSNicoBBurdiRRole of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approachNeuropathol Appl Neurobiol200733334435917493014
  • HodgettsSRadleyHDaviesMGroundsMDReduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx miceNeuromuscul Disord2006169–1059160216935507
  • PiersATLavinTRadley-CrabbHGBakkerAJGroundsMDPinnigerGJBlockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal miceNeuromuscul Disord201121213214121055937
  • MiyatakeSBilanPJPillonNJKlipAContracting C2C12 myotubes release CCL2 in an NF-kappaB-dependent manner to induce monocyte chemoattractionAm J Physiol20163102E160E170
  • De PaepeBCreusKKMartinJJDe BleeckerJLUpregulation of chemokines and their receptors in Duchenne muscular dystrophy: potential for attenuation of myofiber necrosisMuscle Nerve201246691792523225384
  • PorterJDGuoWMerriamAPPersistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscleNeuromuscul Disord200313322323512609504
  • MiyatakeSManabeYInagakiAMacrophage migration inhibitory factor diminishes muscle glucose transport induced by insulin and AICAR in a muscle type-dependent mannerBiochem Biophys Res Commun2014444449650124472542
  • ReimannJSchnellSSchwartzSKappes-HornKDodelRBacherMMacrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathiesJ Neuropathol Exp Neurol201069665466220467327
  • BrzoskaEKowalskiKMarkowska-ZagrajekASdf-1 (CXCL12) induces CD9 expression in stem cells engaged in muscle regenerationStem Cell Res Ther201564625890097
  • ChargeSBRudnickiMACellular and molecular regulation of muscle regenerationPhysiol Rev200484120923814715915
  • GuttridgeDCMayoMWMadridLVWangCYBaldwinASJrNF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexiaScience200028954882363236611009425
  • ThaloorDMillerKJGephartJMitchellPOPavlathGKSystemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injuryAm J Physiol19992772 Pt 1C320C32910444409
  • MourkiotiFKratsiosPLueddeTTargeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regenerationJ Clin Invest2006116112945295417080195
  • ProtoJDTangYLuANF-kappaB inhibition reveals a novel role for HGF during skeletal muscle repairCell Death Dis20156e173025906153
  • ChenGYNunezGSterile inflammation: sensing and reacting to damageNat Rev20101012826837
  • HathoutYMarathiRLRayavarapuSDiscovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patientsHum Mol Genet201423246458646925027324
  • HathoutYBrodyEClemensPRLarge-scale serum protein biomarker discovery in Duchenne muscular dystrophyProc Natl Acad Sci U S A2015112237153715826039989
  • PaepeBDCreusKKWeisJBleeckerJLHeat shock protein families 70 and 90 in Duchenne muscular dystrophy and inflammatory myopathy: balancing muscle protection and destructionNeuromuscul Disord2012221263321855341
  • VidalBSerranoALTjwaMFibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathwayGenes Dev200822131747175218593877
  • VillaltaSARosenthalWMartinezLRegulatory T cells suppress muscle inflammation and injury in muscular dystrophySci transl Med20146258258ra142
  • VetroneSAMontecino-RodriguezEKudryashovaEOsteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-betaJ Clin Invest200911961583159419451692
  • MojumdarKGiordanoCLemaireCDivergent impact of Toll-like receptor 2 deficiency on repair mechanisms in healthy muscle versus Duchenne muscular dystrophyJ Pathol20162391102226800321
  • Henriques-PonsAYuQRayavarapuSRole of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscleHum Mol Genet201423102604261724368419
  • YoungCNBrutkowskiWLienCFP2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatmentJ Cell Mol Med20121651026103721794079
  • JiangTYeungDLienCFGoreckiDCLocalized expression of specific P2X receptors in dystrophin-deficient DMD and mdx muscleNeuromuscul Disord200515322523615725584
  • BuvinicSAlmarzaGBustamanteMATP released by electrical stimuli elicits calcium transients and gene expression in skeletal muscleJ Biol Chem200928450344903450519822518
  • YeungDZablockiKLienCFIncreased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cellsFASEB J200620661062016581969
  • YoungCNSinadinosALefebvreAA novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90Autophagy201511111313025700737
  • RawatRCohenTVAmpongBInflammasome up-regulation and activation in dysferlin-deficient skeletal muscleAm J Pathol201017662891290020413686
  • GazzerroEBaldassariSAsseretoSEnhancement of muscle T regulatory cells and improvement of muscular dystrophic process in mdx mice by blockade of extracellular ATP/P2X axisAm J Pathol2015185123349336026465071
  • PedersenBKFebbraioMAMuscles, exercise and obesity: skeletal muscle as a secretory organNat Rev201288457465
  • KnudsenJGBertholdtLJoensenELassenSBHidalgoJPilegaardHSkeletal muscle interleukin-6 regulates metabolic factors in iWAT during HFD and exercise trainingObesity20152381616162426109166
  • RufoADel FattoreACapulliMMechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humansJ Bone Miner Res20112681891190321509823
  • PelosiLBerardinelliMGDe PasqualeLFunctional and morphological improvement of dystrophic muscle by interleukin 6 receptor blockadeEBioMedicine20152428529326137572
  • PelosiLBerardinelliMGForcinaLIncreased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx miceHum Mol Genet201524216041605326251044
  • KurosakaMMachidaSInterleukin-6-induced satellite cell proliferation is regulated by induction of the JAK2/STAT3 signalling pathway through cyclin D1 targetingCell Proliferat2013464365373
  • KurekJBNouriSKannourakisGMurphyMAustinLLeukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscleMuscle Nerve19961910129113018808655
  • SerranoALBaeza-RajaBPerdigueroEJardiMMunoz-CanovesPInterleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophyCell Metabol2008713344
  • GabayCInterleukin-6 and chronic inflammationArthritis Res Ther20068Suppl 2S316899107
  • PagelCNWasgewatte WijesingheDKTaghavi EsfandouniNMackieEJOsteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscleJ Cell Commun Signal2014829510324318932
  • UaesoontrachoonKWasgewatte WijesingheDKMackieEJPagelCNOsteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injuryDis Model Mech20136119720522917925
  • KuraokaMKimuraENagataTSerum osteopontin as a novel biomarker for muscle regeneration in Duchenne muscular dystrophyAm J Pathol201618651302131226963343
  • PegoraroEHoffmanEPPivaLSPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophyNeurology201176321922621178099
  • BarfieldWLUaesoontrachoonKWuCSEccentric muscle challenge shows osteopontin polymorphism modulation of muscle damageHum Mol Genet201423154043405024626632
  • McPherronACLawlerAMLeeSJRegulation of skeletal muscle mass in mice by a new TGF-beta superfamily memberNature1997387662883909139826
  • ThomasMLangleyBBerryCMyostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferationJ Biol Chem200027551402354024310976104
  • ZimmersTADaviesMVKoniarisLGInduction of cachexia in mice by systemically administered myostatinScience200229655721486148812029139
  • AbeSSoejimaMIwanumaOExpression of myostatin and follistatin in Mdx mice, an animal model for muscular dystrophyZoolog Sci200926531532019715499
  • McCroskerySThomasMMaxwellLSharmaMKambadurRMyostatin negatively regulates satellite cell activation and self-renewalJ Cell Biol200316261135114712963705
  • LangleyBThomasMBishopASharmaMGilmourSKambadurRMyostatin inhibits myoblast differentiation by down-regulating MyoD expressionJ Biol Chem200227751498314984012244043
  • BogdanovichSKragTOBartonERFunctional improvement of dystrophic muscle by myostatin blockadeNature2002420691441842112459784
  • BogdanovichSPerkinsKJKragTOWhittemoreLAKhuranaTSMyostatin propeptide-mediated amelioration of dystrophic pathophysiologyFASEB J200519654354915791004
  • WagnerKRFleckensteinJLAmatoAAA phase I/IItrial of MYO-029 in adult subjects with muscular dystrophyAnn Neurol200863556157118335515
  • CadenaSMTomkinsonKNMonnellTEAdministration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber typeJ Appl Physiol2010109363564220466801
  • LeeSJLeeYSZimmersTARegulation of muscle mass by follistatin and activinsMol Endocrinol201024101998200820810712
  • MendellJRSahenkZMalikVA phase 1/2a follistatin gene therapy trial for Becker muscular dystrophyMol Ther201523119220125322757
  • BartonERMorrisLMusaroARosenthalNSweeneyHLMuscle-specific expression of insulin-like growth factor I counters muscle decline in mdx miceJ Cell Biol2002157113714811927606
  • PelosiLGiacintiCNardisCLocal expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokinesFASEB J20072171393140217264161
  • Lu-NguyenNBJarminSASalehAFPopplewellLGaitMJDicksonGCombination antisense treatment for destructive exon skipping of myostatin and open reading frame rescue of dystrophin in neonatal mdx miceMol Ther20152381341134825959011
  • LongCMcAnallyJRSheltonJMMireaultAABassel-DubyROlsonENPrevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNAScience201434562011184118825123483